ClinicalTrials.gg
CompletedNCT05513586Updated May 19, 2026Results posted

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

A Phase 3 interventional study of TAK-771 in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Completed at 9 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
15th of 18
15 · median 47
Started
2022
with 1 other
Phase 3
9 of 23
none open now
Registered
17th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 17th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

The main aim of the study is to check side effect from the study treatment with TAK-771 in long term.

Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years.

There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant have completed or is about to complete Study TAK-771-3004 (NCT05150340).
  2. Written and/or electronic is obtained from either the participant or the participant's legally authorized representative prior to any study-related procedures and study product administration. If a participant is \<18 years of age, written and/or electronic informed consent should also be obtained from the participant's legally authorized representative in addition to written informed assent by a participant if appropriate.
  3. Participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participant has developed a new serious medical condition during Study TAK-771-3004 such that the participant's safety or medical care would be impacted by participation in the study.
  2. Participant is willing to participate in other clinical trials.
  3. Women of who meet any one of the following criteria:

    1. Participant presents with a positive pregnancy test.
    2. Participant does not agree to employ adequate birth-control measures (eg, intrauterine device, condom [for male partner], or birth-control pills) throughout the course of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    TAK-771

    TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive SC infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution.

    Drug: TAK-771

Interventions

  • Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

    Also known as: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An Adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically significant laboratory finding), symptom, or disease temporally associated with the use of a investigational product, whether or not causality is suspected. A TEAE was defined as any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the investigational product.

    Time frame: From start of study drug administration up to end of study (up to 3.1 years)

  2. Percentage of Participants Who Developed Anti-rHuPH20 Binding Antibody Titers of >=1:160 and Neutralizing Antibodies to rHuPH20

    Participants who developed anti-rHuPH20 binding antibody titers of \>=1:160 and neutralizing antibodies to rHuPH20 was reported.

    Time frame: From start of study drug administration up to end of study (up to 3.1 years)

07

Results

Posted May 19, 2026

Participant flow

A total of 15 participants with primary immunodeficiency diseases (PID) took part in the study in Japan from 13 Sep 2022 to 30 Oct 2025.

Participant flow — Overall Study
MilestoneTAK-771
Started15
Completed12
Not completed3
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An Adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically significant laboratory finding), symptom, or disease temporally associated with the use of a investigational product, whether or not causality is suspected. A TEAE was defined as any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the investigational product.

Time frame:
From start of study drug administration up to end of study (up to 3.1 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsTAK-771
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)100
PrimaryPercentage of Participants Who Developed Anti-rHuPH20 Binding Antibody Titers of >=1:160 and Neutralizing Antibodies to rHuPH20

Participants who developed anti-rHuPH20 binding antibody titers of \>=1:160 and neutralizing antibodies to rHuPH20 was reported.

Time frame:
From start of study drug administration up to end of study (up to 3.1 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed Anti-rHuPH20 Binding Antibody Titers of >=1:160 and Neutralizing Antibodies to rHuPH20
percentage of participantsTAK-771
Anti-rHuPH20 Binding Antibody Titers of >=1:1600
Neutralizing Antibodies0

Adverse events

Collected over From start of study drug administration up to end of study (up to 3.1 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-7710/15 (0%)6/15 (40%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventTAK-771
Adrenal insufficiencyEndocrine disorders1/15
COVID-19Infections and infestations1/15
DiarrhoeaGastrointestinal disorders1/15
Eyelid ptosisEye disorders1/15
HypoglycaemiaMetabolism and nutrition disorders1/15
Inflammatory bowel diseaseGastrointestinal disorders1/15
Joint dislocationInjury, poisoning and procedural complications1/15
PneumoniaInfections and infestations1/15
VomitingGastrointestinal disorders1/15
Most frequent other events
Showing 10 of 83
Most frequent other events
EventTAK-771
NasopharyngitisInfections and infestations9/15
PyrexiaGeneral disorders7/15
COVID-19Infections and infestations6/15
InfluenzaInfections and infestations4/15
Injection site erythemaGeneral disorders4/15
Injection site painGeneral disorders4/15
HeadacheNervous system disorders3/15
Upper respiratory tract infectionInfections and infestations3/15
ArthralgiaMusculoskeletal and connective tissue disorders2/15
Arthropod biteInjury, poisoning and procedural complications2/15

Baseline characteristics

Safety Analysis Set for Extension Study (EXSAS) included all enrolled participants who received investigational drug in Study TAK-771-3005 at least once.

Age, Continuous
Age, Continuous(years)TAK-771
Mean22.7 ± 14.19
Sex: Female, Male
Sex: Female, Male(Participants)TAK-771
Female5
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAK-771
Hispanic or Latino0
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAK-771
American Indian or Alaska Native0
Asian15
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

9 sites
  • Nagoya University Hospital
    Nagoya, Aichi-ken, Japan
  • Hospital of University of Occupational and Environmental Health
    Kitakyushu, Fukuoka, Japan
  • Kanagawa Children's Medical Center
    Yokohama, Kanagawa, Japan
  • Tokyo Medical Dental University Hospital
    Bunkyo-ku, Tokyo, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Gifu University Hospital
    Gifu, Japan
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Saitama Prefectual Children's Medical Center
    Saitama, Japan
  • Shizuoka Childrens Hospital
    Shizuoka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Oct 2025, 37 months.

Results were first posted in May 2026, 6 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 24, 2022
StartActual
Sep 13, 2022
Primary completionActual
Oct 30, 2025
CompletionActual
Oct 30, 2025
Results first posted
May 19, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05513586
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Sep 13, 2022
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Results posted
May 19, 2026
Last update
May 19, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion